Patents by Inventor Arkadiusz Z. Dudek

Arkadiusz Z. Dudek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INSULIN-LIKE GROWTH FACTOR-CHEMOTHERAPEPUTIC CONJUGATE FOR TREATING MYELODYSPLASTIC SYNDROME
    Publication number: 20220211862
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 7, 2022
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek
  • Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
    Patent number: 11324834
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: May 10, 2022
    Assignee: IGF Oncology, LLC
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek
  • INSULIN-LIKE GROWTH FACTOR-CHEMOTHERAPEPUTIC CONJUGATE FOR TREATING MYELODYSPLASTIC SYNDROME
    Publication number: 20180333501
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Application
    Filed: June 12, 2018
    Publication date: November 22, 2018
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek